<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908167</url>
  </required_header>
  <id_info>
    <org_study_id>RELHEM</org_study_id>
    <secondary_id>R01CA138744</secondary_id>
    <secondary_id>NCI-2011-01252</secondary_id>
    <nct_id>NCT00908167</nct_id>
  </id_info>
  <brief_title>Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies</brief_title>
  <official_title>A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer/Onyx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study that determines a tolerable combination of sorafenib, when given&#xD;
      sequentially with cytarabine and clofarabine and determines the feasibility of administering&#xD;
      this drug combination in patients with relapsed or refractory hematologic malignancies&#xD;
      including acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute&#xD;
      lymphoblastic leukemia (ALL), infantile leukemia (both either AML and/or ALL). AML with prior&#xD;
      myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms, and&#xD;
      biphenotypic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research is performed in patients with age of ≥ 0 months old and &lt; 31 years old. In course 1,&#xD;
      sorafenib will be given orally (PO) on days 1 to 7. Pharmacokinetic studies on days 1 and 7&#xD;
      and pharmacodynamic assessment on day 8 will be performed. Inter-patient dose escalation or&#xD;
      de-escalation of clofarabine and sorafenib will be performed based on tolerability and&#xD;
      toxicity. On days 8 to 12, clofarabine and cytarabine will be administered intravenously (IV)&#xD;
      without concurrent twice daily sorafenib. Sorafenib will then be given on days 15 to 28 (14&#xD;
      days). Cytarabine and clofarabine may be given before day 8 when the treating physician feels&#xD;
      it is necessary after consulting with the primary investigator based on the participant's&#xD;
      clinical condition (e.g. disease progression). Intrathecal (IT) methotrexate (age-adjusted&#xD;
      doses) with leucovorin rescue (24 and 30 hours after IT therapy) can be given on day 8.&#xD;
      Participants with central nervous system (CNS) disease can receive IT therapy weekly until&#xD;
      the cerebrospinal fluid (CSF) becomes free of leukemia (minimum of 4 doses). Triple&#xD;
      intrathecal therapy with methotrexate, hydrocortisone and cytarabine is allowed other than&#xD;
      day 8 therapy.&#xD;
&#xD;
      Response evaluation will be performed on day 22 (or 15 days after initiation of cytarabine&#xD;
      and clofarabine) in the first course. One course of therapy will be for 28 days unless&#xD;
      disease progression is seen. Participants may receive subsequent courses (up to 5 courses) if&#xD;
      there is no disease progression or unacceptable toxicity. Sorafenib is given on days 1 to 7&#xD;
      and 15 to 28 in subsequent courses, and cytarabine with or without clofarabine will be&#xD;
      administered starting on days 8 to 12 (clofarabine can be removed after course 2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize a tolerable dose of sorafenib when given in combination with cytarabine and clofarabine in patients with relapsed/refractory hematologic malignancies.</measure>
    <time_frame>4.5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Infantile Leukemia (Both AML and ALL)</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Biphenotypic Leukemia</condition>
  <arm_group>
    <arm_group_label>Research Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants treated with sorafenib, cytarabine and clofarabine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Please see detailed description.</description>
    <arm_group_label>Research Participants</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Research Participants</arm_group_label>
    <other_name>Cytosine Arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Research Participants</arm_group_label>
    <other_name>Clolar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a diagnosis of acute myeloid leukemia (AML), acute promyelocytic&#xD;
             leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (either AML or&#xD;
             ALL), AML with prior myelodysplastic syndrome (MDS),&#xD;
             myelodysplastic/myeloproliferative neoplasms, or biphenotypic leukemia. Patients with&#xD;
             treatment-related AML (t-AML) will be eligible, provided they meet all other&#xD;
             eligibility criteria.&#xD;
&#xD;
          -  Current disease status must be one for which there is no known curative therapy or&#xD;
             therapy proven to prolong survival with an acceptable quality of life.&#xD;
&#xD;
        Patients must meet one of the following criteria:&#xD;
&#xD;
          1. First or greater relapse,&#xD;
&#xD;
          2. Refractory to 1 or more courses of induction or reinduction chemotherapy, or&#xD;
&#xD;
          3. First or greater relapse after allogeneic hematopoietic stem cell transplantation&#xD;
             (HSCT).&#xD;
&#xD;
               -  Age: participants must be &lt; 31 years of age at the time of study entry.&#xD;
&#xD;
        St. Jude participants will include the following:&#xD;
&#xD;
          -  Participants currently on therapy at St. Jude, or within 3 years of completing therapy&#xD;
             at St. Jude must be ≤ 24 years of age.&#xD;
&#xD;
          -  Other participants must be ≤ 21 years of age.&#xD;
&#xD;
        Performance status: Karnofsky &gt;50% for ≥ 16 years of age; Lansky &gt;50% for children &lt;16&#xD;
        years of age.&#xD;
&#xD;
        Organ Function Requirements:&#xD;
&#xD;
          1. Hepatic:&#xD;
&#xD;
               -  Serum direct bilirubin ≤2.0 mg/dl.&#xD;
&#xD;
               -  Alanine transaminase (ALT/SGPT) ≤4 x ULN&#xD;
&#xD;
          2. Cardiovascular:&#xD;
&#xD;
             • Shortening fraction of greater than or equal to 25% by echocardiogram&#xD;
&#xD;
          3. Pulmonary:&#xD;
&#xD;
             • Pulse oximetry ≥93% at room air&#xD;
&#xD;
          4. Renal:&#xD;
&#xD;
             • Creatinine clearance or radioisotope GFR greater than or equal to 70 mL/min/1.73m2&#xD;
             or serum creatinine based on age&#xD;
&#xD;
          5. Pancreas:&#xD;
&#xD;
               -  Amylase and lipase ≤ 2 × upper limits of normal&#xD;
&#xD;
        Participant or legal guardian, in the opinion of the investigator, is capable of&#xD;
        understanding the investigational nature, potential risks and benefits of the study, and&#xD;
        able to provide valid informed consent. A signed informed consent must be obtained prior to&#xD;
        any study specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have relapsed while on sorafenib therapy.&#xD;
&#xD;
          -  Uncontrolled hypertension, defined below:&#xD;
&#xD;
          -  Patients &lt; 18 years old:&#xD;
&#xD;
               -  Diastolic Blood Pressure Within The Upper Limit Of Normal Defined as: A diastolic&#xD;
                  blood pressure (DBP) &gt; the 95th percentile for age and gender despite optimal&#xD;
                  medical management.&#xD;
&#xD;
          -  Patients ≥ 18 years old&#xD;
&#xD;
               -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mmHg or&#xD;
                  diastolic pressure &gt; 90 mmHg despite optimal medical management. .&#xD;
&#xD;
          -  Use of concomitant chemotherapy, investigational agents, radiation therapy, or&#xD;
             immunotherapy other than as specified in the protocol.&#xD;
&#xD;
          -  Use of investigational agents within 30 days or any anticancer therapy within 2 weeks&#xD;
             before study entry with the exception of hydroxyurea, low dose cytarabine and&#xD;
             intrathecal chemotherapy.&#xD;
&#xD;
          -  Any other severe concurrent disease, or have a history of serious organ dysfunction or&#xD;
             disease involving the heart, kidney, liver, or other organ system that may place the&#xD;
             participant at undue risk to undergo treatment.&#xD;
&#xD;
          -  Participant with a systemic fungal, bacterial, viral or other infection not controlled&#xD;
             (defined as exhibiting ongoing signs/symptoms related to the infection and without&#xD;
             improvement), despite appropriate antibiotics or other treatment).&#xD;
&#xD;
          -  Any significant concurrent disease, illness, or psychiatric disorder that would&#xD;
             compromise participant safety or compliance, interfere with consent, study&#xD;
             participation, follow-up, or interpretation of study results.&#xD;
&#xD;
          -  Participants must not receive concomitant medications known to inhibit platelet&#xD;
             function or known to selectively inhibit cyclooxygenase-2 (COX-2) activity (i.e., all&#xD;
             antipyretic and anti-inflammatory medications except acetaminophen).&#xD;
&#xD;
          -  There is no available information, as yet, regarding human fetal or teratogenic&#xD;
             toxicities. Pregnancy tests with a negative result must be obtained in girls who are&#xD;
             postmenarchal within 10 days before start of treatment. Women of childbearing&#xD;
             potential and men must agree to use adequate contraception (barrier method of birth&#xD;
             control) prior to study entry and for the duration of study participation. Men and&#xD;
             women should use adequate birth control for at least three months after the last&#xD;
             administration of study treatment.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Thrombolic or embolic events such as a cerebrovascular accident including transient&#xD;
             ischemic attacks within the past 6 months&#xD;
&#xD;
          -  Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have&#xD;
             unstable angina (anginal symptoms at rest) or new onset angina (began within the last&#xD;
             3 months) or myocardial infarction within the past 6 months.&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.&#xD;
&#xD;
          -  Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             study drug.&#xD;
&#xD;
          -  Concomitant use of St. John's Wort or rifampin (rifampicin)&#xD;
&#xD;
          -  Known or suspected allergy to any agent given in the course of this trial.&#xD;
&#xD;
          -  Any malabsorption problem.&#xD;
&#xD;
          -  Have had a diagnosis of another malignancy, unless the participant has been&#xD;
             disease-free for at least 3 years following the completion of curative intent therapy&#xD;
             with the following exceptions:&#xD;
&#xD;
               -  Participants with treated non-melanoma skin cancer, in situ, carcinoma, or&#xD;
                  cervical intraepithelial neoplasia, regardless of the disease-free duration, are&#xD;
                  eligible for this study if definitive treatment for the condition has been&#xD;
                  completed.&#xD;
&#xD;
               -  Patients with organ-confined prostate cancer with no evidence of recurrent or&#xD;
                  progressive disease based on prostate-specific antigen (PSA) values are also&#xD;
                  eligible for this study if hormonal therapy has been initiated or a radical&#xD;
                  prostatectomy has been performed.&#xD;
&#xD;
          -  Participants who in the opinion of the investigator may not be able to comply with the&#xD;
             safety monitoring requirements of the study.&#xD;
&#xD;
          -  Inability or unwillingness of research participant or legal guardian or representative&#xD;
             to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroto Inaba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sorafenib</keyword>
  <keyword>cytarabine</keyword>
  <keyword>clofarabine</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>acute promyelocytic leukemia</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

